Re-expression of miR34 in this population triggers a loss of the CSC population, as demonstrated by a marked reduction in the CD44+/CD133+ subset, as well as inhibition of spherule formation and in vivo tumor growth. The gene discussed is PROM1; the disease is neoplasm.